Literature DB >> 21531729

Bi-specific aptamers mediating tumor cell lysis.

Achim Boltz1, Birgit Piater, Lars Toleikis, Ralf Guenther, Harald Kolmar, Bjoern Hock.   

Abstract

Antibody-dependent cellular cytotoxicity plays a pivotal role in antibody-based tumor therapies and is based on the recruitment of natural killer cells to antibody-bound tumor cells via binding of the Fcγ receptor III (CD16). Here we describe the generation of chimeric DNA aptamers that simultaneously bind to CD16α and c-Met, a receptor that is overexpressed in many tumors. By application of the systematic evolution of ligands by exponential enrichment (SELEX) method, CD16α specific DNA aptamers were isolated that bound with high specificity and affinity (91 pm-195 nm) to their respective recombinant and cellularly expressed target proteins. Two optimized CD16α specific aptamers were coupled to each of two c-Met specific aptamers using different linkers. Bi-specific aptamers retained suitable binding properties and displayed simultaneous binding to both antigens. Moreover, they mediated cellular cytotoxicity dependent on aptamer and effector cell concentration. Displacement of a bi-specific aptamer from CD16α by competing antibody 3G8 reduced cytotoxicity and confirmed the proposed mode of action. These results represent the first gain of a tumor-effective function of two distinct oligonucleotides by linkage into a bi-specific aptamer mediating cellular cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21531729      PMCID: PMC3122244          DOI: 10.1074/jbc.M111.238261

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  80 in total

Review 1.  Strategies to extend plasma half-lives of recombinant antibodies.

Authors:  Roland E Kontermann
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

2.  G-rich oligonucleotides for cancer treatment.

Authors:  Paula J Bates; Enid W Choi; Lalitha V Nayak
Journal:  Methods Mol Biol       Date:  2009

Review 3.  Modulating the pharmacokinetics of therapeutic antibodies.

Authors:  A Constantinou; C Chen; M P Deonarain
Journal:  Biotechnol Lett       Date:  2010-02-04       Impact factor: 2.461

4.  Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.

Authors:  Justin P Dassie; Xiu-Ying Liu; Gregory S Thomas; Ryan M Whitaker; Kristina W Thiel; Katie R Stockdale; David K Meyerholz; Anton P McCaffrey; James O McNamara; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2009-08-23       Impact factor: 54.908

Review 5.  MET receptor tyrosine kinase as a therapeutic anticancer target.

Authors:  Christine M Stellrecht; Varsha Gandhi
Journal:  Cancer Lett       Date:  2008-12-18       Impact factor: 8.679

6.  Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells.

Authors:  Andrés López-Albaitero; Steve C Lee; Sarah Morgan; Jennifer R Grandis; William E Gooding; Soldano Ferrone; Robert L Ferris
Journal:  Cancer Immunol Immunother       Date:  2009-03-25       Impact factor: 6.968

Review 7.  Bispecific T-cell engaging antibodies for cancer therapy.

Authors:  Patrick A Baeuerle; Carsten Reinhardt
Journal:  Cancer Res       Date:  2009-06-09       Impact factor: 12.701

8.  FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck.

Authors:  Rodney J Taylor; Siaw-Lin Chan; Aaron Wood; Caroline J Voskens; Jeffrey S Wolf; Wei Lin; Andrei Chapoval; Dan H Schulze; Guoliang Tian; Scott E Strome
Journal:  Cancer Immunol Immunother       Date:  2008-11-01       Impact factor: 6.968

9.  Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells.

Authors:  Jiehua Zhou; Piotr Swiderski; Haitang Li; Jane Zhang; C Preston Neff; Ramesh Akkina; John J Rossi
Journal:  Nucleic Acids Res       Date:  2009-03-21       Impact factor: 16.971

10.  Cancer-selective antiproliferative activity is a general property of some G-rich oligodeoxynucleotides.

Authors:  Enid W Choi; Lalitha V Nayak; Paula J Bates
Journal:  Nucleic Acids Res       Date:  2009-12-11       Impact factor: 16.971

View more
  31 in total

Review 1.  Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective.

Authors:  Somayeh Vandghanooni; Morteza Eskandani; Jaleh Barar; Yadollah Omidi
Journal:  J Mol Med (Berl)       Date:  2018-07-28       Impact factor: 4.599

2.  Self-assembled aptamer-based drug carriers for bispecific cytotoxicity to cancer cells.

Authors:  Guizhi Zhu; Ling Meng; Mao Ye; Liu Yang; Kwame Sefah; Meghan B O'Donoghue; Yan Chen; Xiangling Xiong; Jin Huang; Erqun Song; Weihong Tan
Journal:  Chem Asian J       Date:  2012-04-11

Review 3.  Targeting natural killer cells in cancer immunotherapy.

Authors:  Camille Guillerey; Nicholas D Huntington; Mark J Smyth
Journal:  Nat Immunol       Date:  2016-08-19       Impact factor: 25.606

4.  Dimerization of an aptamer generated from Ligand-guided selection (LIGS) yields a high affinity scaffold against B-cells.

Authors:  Sana Batool; Kimon V Argyropoulos; Roksana Azad; Precious Okeoma; Hasan Zumrut; Sanam Bhandari; Rigzin Dekhang; Prabodhika R Mallikaratchy
Journal:  Biochim Biophys Acta Gen Subj       Date:  2018-10-17       Impact factor: 3.770

Review 5.  Nucleic acid aptamers: an emerging frontier in cancer therapy.

Authors:  Guizhi Zhu; Mao Ye; Michael J Donovan; Erqun Song; Zilong Zhao; Weihong Tan
Journal:  Chem Commun (Camb)       Date:  2012-11-04       Impact factor: 6.222

6.  Ligand-guided selection of aptamers against T-cell Receptor-cluster of differentiation 3 (TCR-CD3) expressed on Jurkat.E6 cells.

Authors:  Hasan E Zumrut; Mst N Ara; George E Maio; Nabeela A Van; Sana Batool; Prabodhika R Mallikaratchy
Journal:  Anal Biochem       Date:  2016-08-09       Impact factor: 3.365

Review 7.  Utility of Multivalent Aptamers to Develop Nanoscale DNA Devices against Surface Receptors.

Authors:  Lina Freage; Natalie Boykoff; Prabodhika Mallikaratchy
Journal:  ACS Omega       Date:  2021-05-04

8.  Cell-specific aptamers as emerging therapeutics.

Authors:  Cindy Meyer; Ulrich Hahn; Andrea Rentmeister
Journal:  J Nucleic Acids       Date:  2011-08-28

Review 9.  Generating aptamers by cell-SELEX for applications in molecular medicine.

Authors:  Mao Ye; Jun Hu; Minyuan Peng; Jing Liu; Jun Liu; Huixia Liu; Xielan Zhao; Weihong Tan
Journal:  Int J Mol Sci       Date:  2012-03-12       Impact factor: 6.208

10.  Natural killer cells modulation in hematological malignancies.

Authors:  Céline Baier; Aurore Fino; Carole Sanchez; Laure Farnault; Pascal Rihet; Brigitte Kahn-Perlès; Régis T Costello
Journal:  Front Immunol       Date:  2013-12-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.